UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-17

Dalts,

Yes, but if an unexpected setback happens during the EMA P2 trial...then your prospects for new indications also get impacted negatively.

"Data from this DMD trial will help progress ATL1102 into other indications."

How much more "Data" do we need?

- We have 2 x Phase 2 trials in the bag....MS & DMD
- Full proteomics data...
- Murdoch Institute data due to land Q1

The science has been laid out for all to see.

The patents are locked up.

I also don't believe we need lots of $$$ for new indications.

We need an elephant hunter to help Diamond pursue BigPharma.

What happened to the investment in "resources / talent" Moses mentioned in 2020 AGM?

Board appointments do not work "in the business"....Diamond, Nuket and George can only do so much.

There has been zero investment in new talent.

Now...you can argue we shouldn't do "deals" before futility....we would have stronger negotiating power if DMD futility is positive...BUT ...what if futility is borderline / neutral?

Anyways, seeing as though both Sarepta and Pfizer are on the nose with Gene Therapy, I'm expecting one of them will partner for the FDA arm of the trial.

$100m market cap for the ATL assets at P3 status....is unbelievable.

Especially when you compare to ACW, IHL, IMU etc.

.